In Q1, LEO Pharma continued its robust growth ... advancing innovation through the newly formed strategic partnership with Gilead for the STAT6 program, and significantly improving profitability ...

HOOKIPA Pharma (HOOK) stock gains as Gilead Sciences agrees to acquire some of its antiviral assets for up to $10M. Read more ...

Another Big Pharma is opening up its wallet to pour billions into its U.S. operations amid political pressure from the Trump administration. This time it’s Gilead coming to the table with a ...

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

Leo Pharma has shared phase 2b data on its eczema prospect temtokibart, reporting that the top three doses of the IL-22RA1 blocker beat placebo on the primary endpoint. Temtokibart is designed to ...

LEO Pharma has reported positive topline outcomes from the randomised Phase IIb trial of the IL-22 receptor subunit alpha 1 (IL-22RA1) antagonist temtokibart, a potential new treatment for the ...

LEO Pharma A/S, a global leader in medical dermatology, today announced positive topline results of the phase 2b trial with temtokibart, an investigational IL-22RA1 antagonist, for the potential ...

At LEO Pharma, we have made significant progress on our transformation journey. With our strategy on the right track, we have reached a point on our journey that requires a focus on the long term ...

The EMA has started a review of Leo Pharma’s interleukin-13 inhibitor tralokinumab as an antibody therapy for atopic dermatitis, a category that is currently dominated by Sanofi and Regeneron ...

Drugmaker Gilead is adding to its promised investments in the U.S., vowing to spend another $11B on top of the $21B it has already committed to research, development and manufacturing.